Pharmacist Dermatology On-Demand 1h

New medications for atopic dermatitis (eczema) have emerged. This course reviews new biologics and Janus kinase (JAK) inhibitors and gives you the information you need to make the right treatment decisions and impact patient adherence. 

Learning Objectives

Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Review recent pathophysiological findings in Atopic Dermatitis (AD) that have produced new therapeutic targets.
2. Explain the mechanisms of action and clinical profiles of new and emerging targeted systemic agents for the long-term treatment of AD in adult and pediatric patients.
3. Discuss how adherence barriers play a role in long-term treatment decision-making for adults and pediatric patients with AD.
4. Review comorbidity considerations for treatment decision-making based on the most recent guidance for AD.
5. Recommend pharmacologic and nonpharmacologic therapy for a patient with AD.

Faculty

Geoff Wall, PharmD, FCCP, BCPS

Professor of Pharmacy Practice
Iowa Methodist Medical Center

Disclosures:

Geoff Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.

Course Details